Gilead to buy biotech Pharmasset for $11 billion
by admin on Monday, November 21st, 2011 | No Comments
(Reuters) – Gilead Sciences Inc struck a deal to buy biotechnology company Pharmasset for about $11 billion in a huge bet to diversify its portfolio with new hepatitis C treatments.
View full post on Reuters: Business News
